Genome Sequencing Germany: Providers, Costs & Differences | YEARS
Genome sequencing in Germany has made the leap from the research lab into clinical practice. It is becoming a reality for patients with rare diseases, in modern oncology, and increasingly in…
Genome Sequencing in Germany: Providers, Costs, and Medical Value
Genome sequencing in Germany has made the transition from the research laboratory into medical practice. It is becoming a reality for patients with rare diseases, in modern oncology, and increasingly also in preventive medicine.
The market is confusing. There are major differences between government-funded programs at university hospitals, highly specialized laboratories, and low-cost online offers from abroad when it comes to quality, clinical value, and medical support. What exactly does Whole Genome Sequencing (WGS) mean? How much does it cost, and who pays for it? How can you identify a reputable provider?
This article explains the methods, outlines the costs, and shows the differences between providers. The most valuable information in your genome is not the raw sequence. It is the medical interpretation that turns data into information relevant to your health.
What Is Genome Sequencing? WGS, WES, and Gene Panels Compared
When people talk about “genome sequencing,” three different methods are often mixed together, even though they differ fundamentally in scope, cost, and clinical value. Modern WGS, WES, and larger panel tests usually rely on Next-Generation Sequencing (NGS), in which millions of DNA fragments are read in parallel and analyzed bioinformatically.
Whole Genome Sequencing (WGS): The most comprehensive method. It analyzes nearly the entire genome with its roughly three billion base pairs. This includes protein-coding genes as well as large parts of the non-coding genome. Some of these regions have regulatory functions; for many others, their clinical significance is still not sufficiently understood.
Whole Exome Sequencing (WES): The exome contains the instructions for making proteins and represents about 1–2% of the genome. A large proportion of currently known disease-causing variants are located in these protein-coding regions. WES is therefore an efficient approach for identifying many monogenic diseases, meaning diseases that are largely caused by changes in a single gene.
Gene Panel: This involves analyzing a targeted selection of 10 to more than 500 known genes associated with a specific disease pattern. Typical examples include cancer-risk panels for hereditary breast or colorectal cancer and cardiovascular genetics panels. They are more targeted and often less expensive, but they do not detect relevant variants in genes outside the selected panel.
Sequencing itself produces large amounts of raw genetic data. The medical value emerges in the next step: bioinformatic analysis and clinical interpretation. Relevant variants are filtered out, compared with scientific databases, and assessed in the context of the individual’s health and family history.
Medical Applications: What Is Genome Sequencing Used for in Germany?
Several areas are particularly relevant in Germany.
Rare Diseases
For patients who have often already gone through years of diagnostic testing, exome and genome sequencing have become important components of diagnostic workups. Depending on the suspected diagnosis, they can now be used relatively early in the diagnostic process.
Germany’s pilot program under Section 64e SGB V started in July 2024. Its aim is to integrate genomic medicine into the care of people with rare diseases and cancer in a structured way, and it is being implemented at specialized medical centers. (bundesgesundheitsministerium.de)
Oncology
Two approaches are relevant here. Tumor genomics analyzes genetic changes in cancer cells, meaning somatic mutations, to obtain diagnostic information or identify potential targeted therapies.
Germline diagnostics, by contrast, examines inherited genetic variants that may be associated with hereditary cancer risk, such as BRCA1/2 in breast and ovarian cancer or Lynch syndrome genes in colorectal cancer. Such findings may also be relevant for blood relatives.
Pharmacogenetics
Why does a drug work well in one person but less well in another, or cause stronger side effects? Part of these differences can be explained by genetic variants that influence the absorption, transport, effect, or breakdown of certain medications.
Genes in the CYP450 enzyme family, such as CYP2D6 or CYP2C19, are particularly well known. Pharmacogenetic analyses can provide information for numerous drugs about whether genetic variants may be relevant to dosing, effectiveness, or the risk of side effects. However, they cannot predict with certainty how an individual person will respond to a medication.
Prevention & Longevity
An increasingly offered use case is the estimation of future disease risks in currently healthy individuals.
Alongside rare genetic variants with strong effects, polygenic risk scores (PRS) are used. They combine the effects of a large number of genetic variants and estimate genetic predisposition to complex diseases such as coronary heart disease, type 2 diabetes, or certain cancers.
A PRS is a statistical risk estimate, not a diagnosis. Its predictive value depends, among other things, on the population used, the particular score, and the disease being assessed. Especially in people whose genetic ancestry differs from the population in which a score was developed, predictive performance may be lower. (nature.com)
Genome Sequencing Providers in Germany: An Overview
The market can broadly be divided into three types of providers that differ in service, medical involvement, and legal framework.
Human Genetics Centers and University Medicine
The traditional medical route. Specialists in human genetics or appropriately qualified physicians supervise the diagnostic process. When there is a medical indication, genetic testing may be covered as part of standard care or, for example, within the pilot program under Section 64e SGB V.
The main focus is on specific medical questions such as rare diseases, hereditary tumor syndromes, or other genetically determined conditions.
Accredited Specialist Laboratories, e.g. CeGaT
Highly specialized commercial laboratories carry out genetic diagnostics for physicians, hospitals, and other medical institutions. CeGaT, for example, is accredited under DIN EN ISO 15189, among other standards, and offers both exome and genome diagnostics. Diagnostic testing requires a physician’s order. (cegat.com)
Direct-to-Consumer Providers, e.g. Dante Labs or Nebula Genomics
International providers now make Whole Genome Sequencing available for a few hundred euros or US dollars. Unlike in the past, many of these companies now also provide automated health and pharmacogenetic reports.
Dante Labs, for example, offers 30× WGS with more than 200 available reports. DNA Complete/Nebula offers different sequencing depths depending on the plan, along with several hundred automated reports. (dantelabs.com)
This is still different from physician-ordered and clinically interpreted human genetic diagnostics in Germany. In particular, potentially disease-relevant results from consumer tests should be evaluated by a qualified physician and, if they are relevant to medical decisions, may need to be confirmed with a validated diagnostic method.
Genome Sequencing Costs in Germany: How Much Do WGS, WES, and Gene Panels Cost?
Pricing is complex because sequencing, coverage, bioinformatics, interpretation, and genetic counseling all contribute to the total cost.
Whole Genome Sequencing (WGS)
The technical cost of sequencing has fallen substantially in recent years. International consumer providers now offer 30× WGS in some cases for a few hundred euros or US dollars. (dantelabs.com)
Medical WGS involves additional costs for bioinformatic evaluation, variant classification, physician interpretation, report generation, and potentially genetic counseling. Clinical total prices can therefore reach the low to mid four-figure range or higher.
A frequently cited German cost analysis dates from 2017. Under the technical conditions of the time, Plöthner and colleagues calculated costs of around €3,858 for a 30× WGS analysis. Due to technological progress, this figure should not be treated as a current market price, but it shows how staff, equipment utilization, and technical infrastructure contribute significantly beyond the pure sequencing cost. (pubmed.ncbi.nlm.nih.gov)
Whole Exome Sequencing (WES)
WES is technically less data-intensive than WGS and can therefore be less expensive. Actual costs depend heavily on whether the service includes sequencing alone or a full clinical interpretation, report, and counseling.
For clinically interpreted self-pay services, it is therefore important to check exactly which services are included in the stated price.
Gene Panels
Gene panels are often less expensive because of their clearly limited analytical scope. The price depends on the number and type of genes analyzed as well as the interpretation workload.
Pharmacogenetic panels are also offered as self-pay services; prices vary considerably depending on scope and provider.
Low-cost DTC offers and clinical human genetic diagnostics are therefore only partly comparable. A consumer WGS test with automated reports is a different medical product from an indication-based test with physician interpretation.
Covered by Insurance or Self-Pay? What GKV and PKV Cover
Statutory Health Insurance (GKV)
Human genetic diagnostics can be covered by statutory health insurance when there is a corresponding medical indication and the relevant requirements for the test are met.
In addition, the pilot program under Section 64e SGB V created a specific care framework for comprehensive genome sequencing in selected patients with rare diseases or cancer. The pilot program has been active since July 2024. (bundesgesundheitsministerium.de)
Genome sequencing performed purely for preventive interest or general longevity purposes is currently not part of routine GKV preventive care.
Private Health Insurance (PKV)
Reimbursement depends on the individual insurance contract, the medical indication, and the specific services billed. When there is a justified medical suspicion, human genetic counseling and genetic diagnostics may be reimbursable.
Comprehensive genome sequencing without a specific medical indication may instead be treated as a self-pay service. A written request for coverage before testing is advisable.
Anyone planning genome sequencing primarily for preventive reasons should therefore initially assume that at least part of the cost will have to be paid out of pocket.
What to Look for When Choosing a Provider
Genome sequencing can provide information with far-reaching consequences for you and potentially your family. Choosing the provider is therefore important.
Medical Support
German genetic diagnostics law distinguishes between diagnostic and predictive genetic testing. Predictive genetic testing is subject to specific physician requirements.
Section 10 of the German Genetic Diagnostics Act generally provides for genetic counseling before and after predictive genetic testing. In individual cases, the person concerned may waive counseling in writing after having first received written information about its contents. (gesetze-im-internet.de)
Especially when testing for future disease risks, qualified medical support is therefore an important quality criterion.
Laboratory Accreditation
For medical diagnostics, you should check whether the laboratory is accredited for the relevant test according to recognized quality standards, for example DIN EN ISO 15189 through the responsible accreditation body.
Accreditation does not prove that every statement in a genetic report is clinically meaningful. It mainly relates to defined quality requirements for laboratory processes and testing procedures.
Quality of the Report
Do you receive only raw data and automated risk scores, or a clinically interpreted report?
Variant classification is particularly important. For medical findings, it should be transparent which variants were classified as pathogenic, likely pathogenic, or variants of uncertain significance and what this classification is based on.
Data Protection
Genetic data are among the most sensitive personal health data.
Check where your data are processed and stored, which legal framework applies, and whether the information may be reused for research or other purposes.
A reputable provider clearly explains which data are stored, how long they are retained, and what permissions you are granting.
Handling Secondary Findings
What happens if comprehensive sequencing identifies a genetic predisposition that was not part of the original reason for testing?
Such secondary findings are an important part of medical genomic diagnostics. The American College of Medical Genetics and Genomics, for example, publishes a regularly updated list of genes for which certain clinically relevant secondary findings may be reported under defined circumstances. (gimjournal.org)
Before testing, it should therefore be clarified which secondary findings will be reported and which information you may prefer not to receive.
Genome Sequencing at YEARS in Berlin: Medical Genetics in a Longevity Context
At YEARS, genomics is not an isolated product. It is one component of a physician-led preventive strategy. Genetic analysis is part of the YEARS Ultimate® program.
Ultimate® uses both Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS). The focus is on clinically relevant information.
Analysis of More Than 170 Risk Genes
The analysis includes genes associated with increased risks of oncological, cardiovascular, and metabolic diseases, among others.
Examples include genes linked to hereditary cancer syndromes or genetic forms of lipid disorders.
Pharmacogenetics for More Than 150 Medications
Pharmacogenetic analysis examines variants that may be relevant to drug metabolism, effectiveness, or the risk of side effects for a wide range of medications.
The result does not replace a physician’s treatment decision, but it can provide additional information for future prescribing. Current Ultimate services list more than 170 analyzed risk genes and pharmacogenetic profiles for more than 150 medications. (years.co)
Genomics in the Context of the Rest of the Diagnostic Data
The difference at YEARS lies in the integration. Genomic data are reviewed during the strategy consultation alongside the rest of the diagnostic information: more than 230 biomarkers, whole-body MRI, biological clocks, microbiome analysis, and performance diagnostics.
In practical terms, this means that the medical significance of a genetic predisposition is considered together with family history, clinical findings, and existing risk factors.
A genetic variant does not change its scientific classification simply because, for example, ApoB or Lp(a) is high or low. However, the consequences for prevention, additional diagnostics, and follow-up may depend on the overall individual risk profile.
The YEARS Ultimate® program also includes monthly personal coaching and three physician check-ins per year. The current program structure also lists continuous monitoring and cryopreservation of more than 70 biological samples. (years.co)
Medical services are billed according to the German GOÄ fee schedule. Whether and to what extent private health insurance reimburses the costs depends on the individual policy and the medical necessity of the specific services.
The YEARS Evolve® program does not include genome sequencing.
What You Need to Know Now
Clarify the method: Understand the difference between a targeted gene panel, exome sequencing, and genome sequencing before comparing offers.
Check the provider: For medically relevant testing, qualified medical support, transparent laboratory standards, and clinical interpretation are essential.
Assess costs realistically: Consumer WGS is now available for a few hundred euros. Clinical genomic diagnostics with physician interpretation are a much more comprehensive product and therefore more expensive.
Context matters: Genetic information should be interpreted together with family history, clinical data, and other relevant risk factors.
Genome sequencing without medical interpretation can provide interesting information. For major health decisions, however, qualified interpretation is needed.
If you are looking for medically supervised genome sequencing as part of a comprehensive longevity program, you can speak with our team.
Sources
- German Federal Ministry of Health. genomDE – The German Genome Initiative and Genome Sequencing Pilot Program under Section 64e SGB V. Current as of 2026. (bundesgesundheitsministerium.de)
- German Federal Ministry of Justice. Genetic Diagnostics Act (GenDG), particularly Sections 7 and 10. (gesetze-im-internet.de)
- CeGaT GmbH. Whole Genome Diagnostics / Exome Diagnostics. Current as of 2026. (cegat.com)
- Dante Labs. Whole Genome Sequencing and Genome Test. Current as of 2026. (dantelabs.com)
- DNA Complete / Nebula Genomics. Whole Genome Sequencing – Offers and Reports. Current as of 2026. (nebula.org)
- Plöthner M, Frank M, von der Schulenburg J-M. Cost analysis of whole genome sequencing in German clinical practice. European Journal of Health Economics. 2017;18:623–633. (pubmed.ncbi.nlm.nih.gov)
- Lee K et al. ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing. Genetics in Medicine. 2025. (gimjournal.org)
- Lennon NJ et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations. Nature Medicine. 2024. (nature.com)
This article is intended for general information and does not replace individual human genetic or medical advice.
